Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The revenue forecast for this year ...

This article presents analytical, Monte Carlo, and empirical evidence on combining recursive and rolling forecasts when linear predictive models are subject to structural change. Using a ...

Recursion Pharmaceuticals (RXRX) posted another year of accelerating losses, with net losses growing at 35.2% per year over the last five years. Despite ongoing red ink, revenue is forecast to climb ...

Recursion Pharmaceuticals reported its second-quarter 2025 earnings with revenue significantly surpassing expectations, while earnings per share (EPS) fell short. The company posted an actual EPS of ...